---
title: 'Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly
  Diagnosed Myeloma: Analysis of the MIDAS Trial'
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39841461/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250123170657&v=2.18.0.post9+e462414
source: Blood
description: In patients with transplant-eligible newly diagnosed multiple myeloma,
  induction therapy with a quadruplet regimen prior to autologous transplant is the
  standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a
  minimal residual disease (MRD)-driven consolidation and maintenance strategy following
  induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD).
  Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD. Between
  December ...
disable_comments: true
---
In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD. Between December ...